Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ECs315 WaferiX
- Development stage
- Phase 1
- Lead developer
- Bod Australia
- Administration
- Sublingual
01
Overview
ECs315 WaferiX (commercially known as Xativa) is a sublingual cannabis wafer developed by Bod Australia in partnership with iX Biopharma. The product incorporates ECs315, a proprietary full-plant cannabidiol (CBD) extract originally sourced from Swiss herbal extracts company Linnea SA, into iX Biopharma's patented WaferiX sublingual wafer delivery platform. Designed to dissolve rapidly under the tongue, the wafer bypasses gastrointestinal breakdown and first-pass hepatic metabolism, offering faster and more predictable absorption compared to traditional oral oils or sprays. ECs315 WaferiX has been evaluated in a Phase 1 clinical trial for safety, tolerability, and pharmacokinetics, and is being developed for indications such as chemotherapy-induced nausea and vomiting (CINV), anxiety, tremor, and chronic inflammatory conditions.
- Brand names
- Xativa
- Other names
- WaferiXsublingual cannabis waferMedicabilis sublingual wafer
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))CNR1 (Cannabinoid receptor 1)GPR55 (G protein-coupled receptor 55)PPARG (Peroxisome proliferator-activated receptor gamma)TRPV1 (Transient receptor potential cation channel subfamily V member 1)
Beyond the preview
Go deeper on ECs315 WaferiX.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ECs315 WaferiX.